RESUMEN
No information is currently available on the safety of the aminoglycoside ribostamycin in pregnancy. We aimed to study the pregnancy outcome of women inadvertently exposed to ribostamycin during the first trimester of pregnancy. In a prospective cohort study, 102 women inadvertently exposed to ribostamycin during the first trimester of pregnancy and an age- and gravidity-matched control group, were enrolled. Study outcomes were gestational age at birth, major and minor malformations, and birth weight. Fetal outcomes were evaluated in 85 women inadvertently exposed to ribostamycin during the first-trimester of pregnancy and in 170 control subjects. Newborns were clinically examined at birth by a neonatologist and by imaging studies if any suspicious abnormalities were noted. There were 4/85 (4.9%) babies born with major malformations in the exposed group and 3/170 (1.8%) in the control group (P=0.7). Gestational age at delivery, rate of minor anomalies, rate of preterm births, and birth weight were not different between groups. In conclusion, similar to what is reported for other aminoglycoside, exposure to ribostamycin during the first-trimester of pregnancy does not appear to increase the risk of adverse fetal outcomes.
Asunto(s)
Antibacterianos/efectos adversos , Exposición Materna , Resultado del Embarazo , Ribostamicina/efectos adversos , Anomalías Inducidas por Medicamentos/etiología , Adulto , Peso al Nacer/efectos de los fármacos , Estudios de Casos y Controles , Femenino , Edad Gestacional , Humanos , Recién Nacido , Embarazo , Primer Trimestre del Embarazo , Estudios Prospectivos , Medición de RiesgoRESUMEN
Twelve strains of a rapidly growing Mycobacterium species were isolated from an outbreak associated with intramuscular injections of an antimicrobial agent and were identified by comparative sequence analysis of rpoB and hsp65. These isolates were identified as Mycobacterium massiliense (100% similarity).
Asunto(s)
Brotes de Enfermedades , Inyecciones Intramusculares/efectos adversos , Infecciones por Mycobacterium/epidemiología , Infecciones por Mycobacterium/microbiología , Mycobacterium/aislamiento & purificación , Ribostamicina/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Proteínas Bacterianas/genética , Chaperonina 60 , Chaperoninas/genética , Niño , Preescolar , ADN Bacteriano/química , ADN Bacteriano/genética , ARN Polimerasas Dirigidas por ADN/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mycobacterium/genética , Filogenia , Ribostamicina/administración & dosificación , Ribostamicina/uso terapéutico , Análisis de Secuencia de ADNAsunto(s)
Anafilaxia/inmunología , Antibacterianos/efectos adversos , Hipersensibilidad a las Drogas/inmunología , Ribostamicina/efectos adversos , Adulto , Anafilaxia/inducido químicamente , Antibacterianos/inmunología , Hipersensibilidad a las Drogas/etiología , Femenino , Humanos , Enfermedad Inflamatoria Pélvica/tratamiento farmacológico , Recurrencia , Ribostamicina/inmunologíaRESUMEN
A 48-year-old man became erythrodermatous after intramuscular administration of ribostamycin, an aminoglycoside antibiotic in the same family as neomycin. Patch tests were positive to ribostamycin and neomycin, as well as to mercurials. There was no mercurial preservative in the injection solution. A lymphocyte transformation test was positive for ribostamycin and tobramycin, but not for gentamycin. Diagnostic and structure-activity relationship aspects of the case are discussed.